Case Solution for The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights

Complete Case details are given below :

Case Name :      The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Authors :           Pedro Matos, Dmitriy Aleyev, Chong Xu
Source :             Darden School of Business
Case ID :           UV6870
Discipline :        Finance
Case Length :    16 pages
Solution Sample availability : YES
Plagiarism : NO (100% Original work)
Description for case is given below :
This case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (CVR). Was a CVR the magical solution to bridging the valuation gap?
Click Here to place your order
Place your order at casesolutionshub (AT)gmail(dot)com if you want to solve above case.
Case Solutions Hub